[PDF][PDF] Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.
AK Thom, HR Alexander, MP Andrich… - Journal of clinical …, 1995 - researchgate.net
Journal of clinical oncology, 1995•researchgate.net
Purpose: Isolated limb perfusion (ILP) with tumor ne-crosis factor (TNF), interferon gamma,
and melphalan (M) has been reported to result in high response rates for extremity
melanoma and sarcoma. We have evaluated the relationship of systemic TNF exposure to
induc-tion of several secondary mediators and incidence of systemic toxicity. Patients and
Methods: Nineteen patients with ex-tremity melanoma (n= 16) or sarcoma (n= 3), under-went
90-minute ILP with TNF-a, interferon gamma (0.2 mg), and M (10 to 13 mg/L of limb …
and melphalan (M) has been reported to result in high response rates for extremity
melanoma and sarcoma. We have evaluated the relationship of systemic TNF exposure to
induc-tion of several secondary mediators and incidence of systemic toxicity. Patients and
Methods: Nineteen patients with ex-tremity melanoma (n= 16) or sarcoma (n= 3), under-went
90-minute ILP with TNF-a, interferon gamma (0.2 mg), and M (10 to 13 mg/L of limb …
Purpose: Isolated limb perfusion (ILP) with tumor ne-crosis factor (TNF), interferon gamma, and melphalan (M) has been reported to result in high response rates for extremity melanoma and sarcoma. We have evaluated the relationship of systemic TNF exposure to induc-tion of several secondary mediators and incidence of systemic toxicity.
Patients and Methods: Nineteen patients with ex-tremity melanoma (n= 16) or sarcoma (n= 3), under-went 90-minute ILP with TNF-a, interferon gamma (0.2 mg), and M (10 to 13 mg/L of limb volume)(TNF/IFN/
researchgate.net